

$\gamma\delta$ T Cells Support Antigen-Specific $\alpha\beta$ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer



Niannian Ji^{1,2}, Neelam Mukherjee^{1,2}, Zhen-Ju Shu^{1,2}, Ryan M. Reyes^{1,3}, Joshua J. Meeks⁴, David J. McConkey⁵, Jonathan A. Gelfond⁶, Tyler J. Curiel^{1,3}, and Robert S. Svatek^{1,2}

ABSTRACT

Bacillus Calmette-Guérin (BCG) is the most effective intravesical agent at reducing recurrence for patients with high-grade, non-muscle-invasive bladder cancer. Nevertheless, response to BCG is variable and strategies to boost BCG efficacy have not materialized. Prior work demonstrated a requirement for either conventional $\alpha\beta$ or nonconventional $\gamma\delta$ T cells in mediating BCG treatment efficacy, yet the importance of T-cell antigen specificity for BCG's treatment effect is unclear. Here, we provide direct evidence to show that BCG increases the number of tumor antigen-specific $\alpha\beta$ T cells in patients with bladder cancer and protects mice from subsequent same-tumor challenge, supporting BCG induction of tumor-specific memory and protection. Adoptive T-cell transfers of

antigen-specific $\alpha\beta$ T cells into immunodeficient mice challenged with syngeneic MB49 bladder tumors showed that both tumor and BCG antigen-specific $\alpha\beta$ T cells contributed to BCG efficacy. BCG-specific antitumor immunity, however, also required nonconventional $\gamma\delta$ T cells. Prior work shows that the mTOR inhibitor rapamycin induces the proliferation and effector function of $\gamma\delta$ T cells. Here, rapamycin increased BCG efficacy against both mouse and human bladder cancer *in vivo* in a $\gamma\delta$ T cell-dependent manner. Thus, $\gamma\delta$ T cells augment antitumor adaptive immune effects of BCG and support rapamycin as a promising approach to boost BCG efficacy in the treatment of non-muscle-invasive bladder cancer.

Introduction

Bacillus Calmette-Guérin (BCG) treatment of bladder cancer was one of the first cancer immunotherapies to demonstrate significant benefit in a large clinical trial (1). The first reported use of BCG in 1970 treated cutaneous melanoma (2), and in 1976, BCG treatment of bladder cancer was described (3). BCG continues to be the standard-of-care treatment for preventing relapse and progression for patients with high-grade, non-muscle-invasive bladder cancer (NMIBC; refs. 1, 3, 4). Nevertheless, BCG fails to completely eradicate disease in many patients (5), and there are no FDA-approved agents proven to boost BCG's antitumor activity. Despite decades of use, the mechanisms of BCG activity are incompletely understood.

The importance of T cells in mediating BCG antitumor activity is supported by experimental models of bladder cancer showing lack of BCG efficacy in T cell-deficient mice (6) and following antibody

depletion of T cells (7). However, the role of antigen specificity in BCG's antitumor activity is unclear. Conventional T cell-based cancer immunotherapy acts through induction of tumor-associated antigen-specific $\alpha\beta$ T cells, which are activated by peptides derived from tumor proteins and presented by MHC molecules on the surface of antigen-presenting cells (8, 9). In BCG cancer immunotherapy, however, an alternative mechanism proposed is that BCG elicits tumor killing through induction of BCG antigen-specific T cells. In this regard, BCG organisms are endocytosed and processed by bladder tumor cells (10). Then, BCG-derived peptides are bound to MHC molecules displayed on the tumor surface (10–13), and tumor destruction occurs via BCG-specific T cells (14). Although this mechanism of antitumor activity is plausible during BCG treatment, direct evidence for BCG-specific antitumor responses in mediating BCG efficacy is lacking (15).

To address this knowledge gap, we developed an experimental model for studying antigen-specific T-cell immunity during BCG treatment of bladder cancer. We discovered that BCG mediates antitumor immunity through both tumor-specific and BCG-specific conventional $\alpha\beta$ T cells *in vivo*. However, nonconventional $\gamma\delta$ T cells were also required for antitumor activity of BCG antigen-specific T cells in our bladder cancer models. Unlike $\alpha\beta$ T cells, recognition of antigen by $\gamma\delta$ T cells is MHC unrestricted (16). $\gamma\delta$ T cells recognize a variety of ligands (17, 18), such as lipids, unprocessed tumor ligands, and small organic phosphate molecules, that are ubiquitous in nature and conserved across many biologic species, including in BCG (19, 20).

Given the contribution of $\gamma\delta$ T cells toward BCG-mediated antigen-specific immunity, we hypothesized that activation of $\gamma\delta$ T cells would boost BCG's antitumor activity. Our group and others have shown that the mTOR inhibitor, rapamycin, increases the proliferation and effector function of $\gamma\delta$ T cells (21–24). In patients with NMIBC, rapamycin enhances BCG-specific $\gamma\delta$ T cells (25). Translating $\gamma\delta$ T-cell activity between species is complex because mouse and human $\gamma\delta$ T cells react differently to mycobacterial antigens (26) and

¹Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson, San Antonio, Texas. ²Department of Urology, UT Health San Antonio, San Antonio, Texas. ³Division of Hematology/Medical Oncology at UT Health San Antonio, San Antonio, Texas. ⁴Departments of Urology, and Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois. ⁵Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, Maryland. ⁶Department of Epidemiology and Biostatistics, UT Health San Antonio, San Antonio, Texas.

Note: Supplementary data for this article are available at Cancer Immunology Research Online (<http://cancerimmunolres.aacrjournals.org/>).

Corresponding Authors: Robert S. Svatek, Department of Urology, UT Health San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229. E-mail: svatek@uthscsa.edu; and Tyler J. Curiel, curiel@uthscsa.edu

Cancer Immunol Res 2021;9:1491–503

doi: 10.1158/2326-6066.CIR-21-0285

©2021 American Association for Cancer Research

Ji et al.

incompletely overlap in nomenclature and development (27). Therefore, we studied effects of rapamycin on $\gamma\delta$ T cells in both murine and human models. We discovered that rapamycin-mediated enhancement of $\gamma\delta$ T-cell function improves BCG treatment efficacy *in vivo* against mouse and human bladder cancer preclinical models.

Materials and Methods

Animals

All animal studies were conducted in accordance with, and with the approval of, an Institutional Animal Care and Use Committee (IACUC) at UT Health San Antonio (San Antonio, TX). Six- to 10-week-old female wild-type (WT), Rag1 knockout (Rag1^{KO}), TCR δ ^{KO}, female/male TCR α ^{KO} on C57BL/6 background, and female/male NSG mice were either purchased from The Jackson Laboratory, or bred under conventional (for WT) or specific pathogen-free housing conditions as described and defined by IACUC protocols (20120040AR and 20150058AR). For all MB49 challenge experiments, unless in the absence of conventional $\alpha\beta$ T cells (TCR α ^{KO}, no gender variation in results), to ensure uncompromised antitumor HY-antigen adaptive response, only females were used, including adoptive transfer studies. For immunodeficient NSG recipients (no significant gender variation), both genders were used to maximize usage of resource. Animals in each study were randomized prior to tumor challenge, and experiments were repeated independently two to three times. Power analysis was used to estimate the minimum sample size required for each experiment or pooled experiments.

Mouse tumor model and cell lines

All cell lines were tested and confirmed free of *Mycoplasma* by Mycoalert PLUS Detection Kit (Lonza Bioscience) during the study but were not genetically authenticated in the past year. Mouse bladder cancer cell line MB49 were generously given by Jeffrey Schlom at NIH in 2013 and maintained in complete DMEM (cDMEM-10) media (Thermo Fisher Scientific) with 10% FBS (HyClone/Thermo Fisher Scientific), penicillin (100 IU/mL) plus streptomycin (100 μ g/mL; Corning), and 2 mmol/L of fresh L-glutamine (Corning). The last test for negative *Mycoplasma* was in June 2018. Once thawed, MB49 cells were cultured for two passages (~48 hours/passage) with approximately 70% confluency and injected subcutaneously into WT, Rag1^{KO}, TCR δ ^{KO}, and TCR α ^{KO} C57BL/6 mice at 0.2×10^6 cells in 100 μ L of PBS per flank on both sides, on the lower back for initial MB49 challenge at day 0 and upper back for tumor rechallenge at days 35 to 45. For the tumor rechallenge control, the mouse melanoma cell line B16-F10 (purchased from ATCC before 2015) was used. The last test for negative *Mycoplasma* was in 2018. Once thawed, B16 cells were cultured for two passages (~48 hours/passage) with approximately 70% confluency in complete RPMI1640 media (Corning) with 5% FBS, penicillin (100 IU/mL) plus streptomycin (100 μ g/mL), and 2 mmol/L L-glutamine. 0.75×10^6 B16 cells in 150 μ L of PBS were injected subcutaneously per flank in WT C57BL/6 mice (upper back). Tumor volume was measured three times a week by a caliper and calculated using formula: volume = length \times width \times width/2 (mm³). Mice were monitored three times per week and daily when tumor volume of any single tumor was over 1,500 mm³. Mice were euthanized when any tumor volume reached 2,000 mm³. For immune studies, mice were euthanized for collection of tumor and tumor-draining lymph nodes (TDLN) either within a week after third BCG treatment, or whenever approximately 50% of tumors in control groups were over 1,000 mm³.

BCG preparation

As described previously (28), live BCG.Connaught (Sanofi; for mouse) and BCG.TICE (Merck & Co; for human) were prepared and cryopreserved, with colony-forming units (CFU) determined after thawing representative vials. BCG vial(s) were thawed and pelleted at 4°C, 7,000 rpm for 10 minutes prior to resuspension in PBS at the desired concentration for each treatment.

Treatment

BCG.Connaught treatment

Starting on day 5 after MB49 tumor challenge, 1×10^6 CFU of BCG in 50 μ L of PBS were injected into each subcutaneous tumor, weekly for 3 weeks.

CD4⁺ and CD8⁺ T-cell depletion

A total of 200 μ g of mAb from BioXcell, either anti-mouse CD4 (clone GK1.5), anti-mouse CD8 (clone YTS169.4), or rat IgG2b isotype mAb (clone LTF-2), were diluted in 100 μ L PBS and injected intraperitoneally per mouse on days 1, 3, 7, and 11 after MB49 tumor challenge.

$\gamma\delta$ T-cell depletion

A total of 75 μ g of anti-mouse TCR γ/δ mAb (BioXcell, clone UC7-13D5) or Armenian Hamster polyclonal isotype IgG (BioXcell) were diluted in 100 μ L of PBS and injected intraperitoneally per mouse starting day 4 after MB49 tumor challenge and every 3 to 4 days for 2 weeks.

Rapamycin

Mice were injected intraperitoneally with 0.075 mg/kg of rapamycin (LC laboratory, stock prepared in EtOH) or 100 μ L vehicle control containing sterile 0.25% PEG-400 (Sigma-Aldrich) and 0.25% Tween-80 (Sigma-Aldrich) in water starting day 3 post-tumor challenge daily, Monday through Friday. For oral treatment, mice were placed on encapsulated rapamycin (eRapa chow; 14 parts per million/ppm; Rapamycin Holdings) or Eudragit control (Rapamycin Holdings) diet 1 week before tumor challenge and throughout the experiment, which contains a concentration of 14 mg/kg food and provides an approximately 2.24 mg of rapamycin/kg body weight/day. Dosing was justified (29, 30) and based on human to animal conversion, considering the human dose of 0.5 mg/day.

Antigen-specific T-cell adoptive transfer mouse model

As described previously (31), to prime antigen-specific T cells, female WT donor mice were immunized subcutaneously on top of each foot with 50 μ L of Incomplete Freund's Adjuvant (Thermo Fisher Scientific)-emulsified HY peptide (100 μ g), OVA protein (100 μ g) as indicated in Supplementary Table S1, or BCG.Connaught (2×10^6 CFU). On day 9, donors were sacrificed, and both inguinal and popliteal draining lymph nodes (DLN) and spleens were harvested and placed in a 60 mm \times 15 mm petri dish containing 10 mL of RPMI1640 media. Both tissues were mashed with the back of a 10 mL syringe, and then passed through a 100- μ m strainer to obtain single-cell suspension for cell counting (ViCell) prior to culture. Red blood cells (RBC) were removed from splenocytes sterily using hypotonic shock: Loose cell pellet was resuspended in 9 mL of H₂O by gentle shaking for 5 seconds, then immediately mixed with 1 mL of 10 \times PBS. Pooled DLNs cells or splenocytes from the same antigen group were cultured at 10×10^6 cells/mL in complete RPMI1640 (cR-10) media with 10% FBS and 2 mmol/L of L-glutamine plus HY peptide

(10 $\mu\text{g}/\text{mL}$), OVA protein (10 $\mu\text{g}/\text{mL}$), or BCG [multiplicity of infection (MOI) of 0.1] in 6-well plates at 37°C with 5% CO_2 . Approximately 50% of the supernatants were carefully removed and replaced with new media every 48 hours. After 5 days, antigen-recalled cells were harvested, recounted, and plated at 5×10^6 cells/mL in cR-10 media containing recombinant mouse IL2 (10 ng/mL; BioLegend). Approximately 30% of the supernatants were replaced with new media containing IL2 (10 ng/mL) every 72 hours. After 7 days, expanded DLN cells and splenocytes were pooled for magnetic enrichment by negative selection (BD, mouse T lymphocyte enrichment kit). Approximately 5×10^6 donor T cells were injected intravenously or intraperitoneally into $\text{TCR}\alpha^{\text{KO}}$ or Rag1^{KO} female recipients in 200 μL PBS per mouse 1 day prior to or after subcutaneous MB49 tumor challenge. After adoptive transfer, the remaining portion of donor T cells was quantified for antigen specificity using cytokine ELISPOT assays.

Mouse antigen-specific ELISPOT assay

As described previously (24), 10,000 cells/well of magnetically enriched donor T cells were mixed with approximately 0.5×10^6 naïve WT female splenocytes (RBC lysed by hypotonic shock as described above) in cR-10 media containing antigen peptide (10 $\mu\text{g}/\text{mL}$; >98% purity) or protein (Supplementary Table S1): class II-restricted HY-Dby peptide, class I-restricted HY-Uty and OVA peptides, BCG-Ag85b protein, OVA protein, or BCG.Connaught (MOI 0.1), at 200 μL final volume/well on capture mAb-coated, BSA-blocked MultiScreen ImmunoSpot plates (EMD), incubated at 37°C with 5% CO_2 for 24 hours. After incubation with detection mAbs and development, IFN γ -producing spot-forming cells were quantified using the ImmunoSpot Analyzer (S6 Micro, Cellular Technology) with ImmunoSpot Software, version 6 (Cellular Technology, RRID: SCR_011082).

Immune analysis for mouse model by flow cytometry

Tumor tissue and/or TDLNs were harvested from WT, Rag1^{KO} , and $\text{TCR}\alpha^{\text{KO}}$ C57BL/6 mice of subcutaneous MB49 tumor model. A total of ≤ 0.5 g of tumor was minced and incubated with 3 mL of serum-free RPMI media containing collagenase IV (1.5 mg/mL; Sigma-Aldrich) and DNase I (0.25 mg/mL; Sigma-Aldrich) at 37°C with 5% CO_2 for 1 hour with gentle shaking/mixing every 15 minutes. TDLNs or digested tumors were mashed with the back of a 10 mL syringe, and then passed through a 100- μm strainer to obtain single-cell suspensions for cell counting (ViCell) and flow cytometry staining using reagents listed in Supplementary Table S1. Samples and reagents were mixed thoroughly by gentle pipetting with large orifice tips prior to each incubation on 96-well U-bottom plate. Any remaining unstained portions were aliquoted and cryopreserved in freezing media freshly prepared each time by mixing cR-10 media with FBS containing 20% DMSO (Thermo Fisher Scientific) at 1:1 ratio. For surface staining, cells were resuspended in ice-cold flow buffer (2% FBS in PBS) at 1×10^6 cells/100 μL /well and incubated with 0.2 μg of mouse Fc-blocker on ice for 15 minutes, followed by incubation of fixable viability dye (FVD; 1:1,000) mixed with 0.1 to 0.2 μg of fluorochrome-conjugated mAbs at 4°C, in the dark for 45 minutes. Samples were washed twice with up to 200 μL of flow buffer and resuspended in 150 μL of fixation buffer (2% paraformaldehyde in PBS) for at least 15 minutes or overnight at 4°C. Prior to analysis, samples were resuspended in flow buffer. For intracellular cytokine detection, single-cell suspensions were incubated with a cell activation cocktail (BioLegend) containing 0.08 $\mu\text{mol}/\text{L}$ of PMA (phorbol 12-myristate 13-acetate), 1.34 $\mu\text{mol}/\text{L}$ of ionomycin, and 5 $\mu\text{g}/\text{mL}$ of Brefeldin A in cR-10 at 1×10^6 cells/100 μL , 37°C for 5 hours prior to flow staining. After surface staining,

cells were incubated with 100 μL of Cytofix/Cytoperm solution at 4°C for 20 minutes, followed by one wash with permeabilization buffer and incubation in 100 μL of permeabilization buffer with 0.2 to 0.3 μg of fluorochrome-conjugated mAbs at 4°C, in the dark for 45 minutes. Samples were washed once with up to 200 μL of permeabilization buffer and resuspended in 150 μL of flow buffer. All samples were run and analyzed on LSRII cytometer (BD) using FACSDiva software (Version 8.0.1). Gating strategies were described in the legends of each corresponding figures with flow dot plot and/or histogram examples using tumor-infiltrating lymphocytes or TDLN cells as indicated. Each T-cell subset (CD4^+ , CD8^+ , or $\gamma\delta$ T cells) was gated under live (FVD^-) $\text{CD45}^+\text{CD3}^+$ population for tumor sample analysis and gated under live (FVD^-) CD3^+ population for TDLN analysis if performed separately, for example, verification of % of T-cell subset after in antibody-depletion experiment. Fluorescence minus one (FMO) controls were included for the expression of any marker on any T-cell subset except for H-2D^b-HY-Uty tetramer staining when an unspecific H-2D^b-peptide negative control was used. Gating threshold of positive population was set to not more than 2% in each FMO control.

Human peripheral blood mononuclear cell and tumor tissue processing and storage

Collection and use of clinical samples from patients with bladder cancer were approved and abided by Institutional Review Boards (IRB), protocol HSC2012-159H for bladder cancer repository, with informed written consent obtained prior to enrollment. The patient studies were conducted in accordance with Declaration of Helsinki ethical guidelines. Eligibility criteria for this repository included any patient with known or suspected bladder cancer. Blood, urine, lymph nodes, and tumors were collected from patients when available. Patients with available tumor tissue and blood upon enrollment, as well as with blood 3 to 6 months after, were selected for analyzing tumor-specific T-cell responses *in vitro*. For the no BCG group: 2 patients had muscle-invasive bladder cancer and received systemic chemotherapy, and the other patient had low-grade NMIBC and did not receive BCG or chemotherapy. All 3 patients (no BCG) progressed and had cystectomy after 4 to 6 months when blood was collected again. For the BCG group: All 3 patients had high-grade NMIBC and were under BCG intravesical treatment, either induction phase (weekly for 6 weeks) or maintenance phase (weekly for 3 weeks). Blood was collected again when the patients returned to clinic for cystoscopy in 3 to 6 months. As described previously (28), peripheral blood mononuclear cells (PBMC) were isolated from plasma-removed, noncoagulated whole blood by Ficoll-Paque (GE Healthcare) and cryopreserved in freshly prepared freezing media (as described above) at -150°C until analyzed. Surgically excised bladder tumors were transported on ice in RPMI medium containing 2% FBS and 1% penicillin-streptomycin. Tumor tissues were washed with PBS, minced, and incubated in 0.05% trypsin/EDTA (1 g of tissue per 5 mL) containing type IV collagenase (1 mg/mL; Sigma-Aldrich) and DNase I (0.25 mg/mL; Sigma-Aldrich) at 37°C, 100 rpm shaking for 1 hour. Digestion was stopped and washed with cR-10 media to obtain single-cell suspensions for cryopreservation in freshly prepared freezing media (as described above) at -150°C until analyzed.

Human tumor-specific responses in autologous patient PBMCs

Patient PBMCs were harvested at the time of tumor collection (baseline/enrollment) and at 3 to 6 months after. 1×10^6 cryopreserved PBMCs were thawed in cR-10 media and labeled with CFSE (Invitrogen, CellTrace), and then cocultured with or without irradiated (25 Gy, γ -irradiator) autologous tumor tissue single-cell suspensions (E:T

Ji et al.

ratio, 10:1) in cR-10 media supplemented with 10% human serum (type-AB, MP Biomedicals) at 37°C with 5% CO₂ for 7 days, followed by 5 hours of restimulation with cell activation cocktail, flow cytometry staining using reagents listed in Supplementary Table S1 (following protocol described above), and analyzed on an LSRII cytometer using FACSDiva software (Version 8.0.1). CD4⁺ and CD8⁺ T cells were gated under FVD⁻CD3⁺ T cells. Proliferating T cells were gated as CFSE^{lo} based on medium only (without addition of irradiated autologous tumor tissue)/control sample. Gating of double-positive for IFN γ and TNF α , or IFN γ and CD107a were based on FMO control gating under CFSE^{lo/-} T cells. Total live cells were quantified before and after 7-day culture for calculating the number of proliferated/CFSE^{lo} T cells that were also positive for IFN γ and TNF α , or CD107a. Tumor responses were normalized/subtracted by media/background responses.

Establishing a patient-derived tumor cell line and model

A fresh tumor sample was processed into a single-cell suspension as described above. Approximately 2×10^6 cells were mixed with Matrigel Matrix (Corning) at 1:1 and injected subcutaneously into NSG mice. Patient-derived xenografts (PDX) were then monitored weekly for tumor growth. When tumors reached 400 mm³ in 2 months, it was resected and processed into single-cell suspensions for *in vitro* culture and expansion in cDMEM-10 media for approximately 2 weeks. The tumor cell line obtained (PDX257S) maintained urothelial carcinoma histology after *in vivo* passage and was confirmed positive for human EpCAM expression. This cell line was not tested for *Mycoplasma* or genetically authenticated. For subcutaneous challenge, PDX257S cells were thawed and cultured in cDMEM-10 media for at least two passages (72 hours/passages) with approximately 80% confluency.

Adoptive transfer of expanded human $\gamma\delta$ T cells from patient PBMCs

$\gamma\delta$ T cells were expanded directly from autologous PBMCs of the PDX donor *in vitro* in cR-10 media with isopentenyl pyrophosphate (IPP) and IL2, with or without rapamycin (0.5 nmol/L; LC Laboratories) or live BCG.TICE (MOI 0.1) following previous protocols (22, 28). On day 14 of culture, $\gamma\delta$ T cells were harvested and mixed with PDX257S tumor cells at a 1:2 ratio and injected subcutaneously into NSG mice (1×10^6 tumor cells each site) on both flanks. Tumor growth was monitored and measured twice a week.

Immune analysis for human $\gamma\delta$ T cells by flow cytometry

D14-expanded $\gamma\delta$ T cells in replicates from the PDX donor PBMCs were resuspended in flow buffer at $0.5-1 \times 10^6$ cells/100 μ L on 96-well U-bottom plate and either stained directly with 0.2 μ g of fluorochrome-conjugated mAbs plus FVD (1:1,000) at 4°C for 45 minutes in the dark after incubated with 5 μ L of human Fc-blocker/TruStain (10 minutes on ice), or stimulated first with cell activation cocktail for 5 hours followed by intracellular cytokine staining using reagents listed in Supplementary Table S1 (in similar steps as described above) and analyzed on an LSRII using FACSDiva software (Version 8.0.1). Gating strategy was described in each corresponding figure legend with example of flow cytometry dot plot and/or histogram. Remaining unstained portions were cryopreserved in freshly prepared freezing media (as described above).

Statistical analysis

Two-sided testing was performed to improve rigor by removing bias in assumptions about the direction of treatment effect. Multiple

corrections were performed by Tukey (all pairs), Dunnett (comparison over control group, >one variable), or Dunn (comparison over control or selected groups, one variable) multiple comparison test, except for comparing mean plus SEM (when $N > 100$, hence Bonferroni multiple comparison). For analysis with one variable, the D'Agostino and Pearson omnibus normality test was used, and if $P > 0.05$, then a parametric *t* test (two groups) or one-way ANOVA with multiple comparison test (> two groups) was used; if $P < 0.05$, then a nonparametric Mann-Whitney test (two groups) or Kruskal-Wallis test with multiple comparison test (> two groups) was used. When not all groups passed normality testing: If more than half passed normality test, a parametric test was used; otherwise, a nonparametric test was used; for any group with $n \leq 7$ (N too small), unless there were substantial outliers in the datasets (nonparametric distribution), it was considered to pass the normality test.

For analysis with more than one variable, interaction tests were used to identify treatment-specific outcome trajectories over time. Two-way ANOVA (two groups) or repeated measures ANOVA (> two groups) with multiple comparison test were used in tumor volume growth curves, except when two sets of pairs started from different timepoints (initial vs. rechallenge) or inner strain comparison occurred involving two different genotypes of mouse pairs. In those cases, repeated measures ANOVA could not be run and a two-way ANOVA was used. Differences over time in BCG versus non-BCG-treated patients for tumor immunity were assessed with two-sided testing based on the group (baseline, 3–6 months) by condition (no BCG, BCG) interaction term in a linear model. Survival curves/Kaplan-Meier plots were assessed by log-rank test. *P* values are two sided and *, $P < 0.05$ was considered statistically significant. Statistical analyses were performed with GraphPad Prism 5–6 or Stata IC/10.1 (GraphPad Prism, RRID: SCR_002798).


Declarations

The studies related to this article were conducted abided by research ethics and approved IACUC or IRB guidelines for animal or clinical sample use. All authors have consent for publishing the data from the studies.

Results

BCG boosts bladder tumor-specific memory

To determine whether BCG increased tumor-specific immunity in patients with bladder cancer, we measured the frequency of tumor antigen-specific T cells (i.e., T cells that proliferated and produced IFN γ and TNF α in response to irradiated autologous bladder tumor antigens; Supplementary Fig. S1) in peripheral blood collected from patients with bladder cancer before and after intravesical BCG. At 3 to 6 months after BCG administration, we observed a significant increase over baseline in the number of circulating tumor-specific T cells in patients who received BCG compared with patients who did not receive BCG (Fig. 1A–C). BCG-mediated induction of tumor-specific antitumor immunity should provide long-term protection against subsequent tumor growth. To test this concept, we used MB49 tumor cells transplanted subcutaneously into C57BL/6 WT female mice, an established model for studying bladder cancer immunopathology (32) and immunotherapy (33), including BCG (14). In MB49-challenged mice treated with BCG, an increase in tumor-specific immunity was observed, detected as an increase in tumor antigen-specific T cells (i.e., H-Y, male-derived tumor antigen-specific) infiltrating tumor tissue (Fig. 1D). Mice that experienced complete MB49 tumor regression after BCG treatment were protected against tumor

$\gamma\delta$ T Cells Support $\alpha\beta$ T Cells during BCG Treatment**Figure 1.**

BCG treatment increases tumor-specific immunity in patients and antitumor protection in a mouse model. **A–C**, As described in “Materials and Methods,” patient PBMCs harvested from baseline and at 3 to 6 months after BCG treatment were measured for tumor-specific responses. Paired samples indicated with lines. Shown are absolute numbers (AN) of proliferating CD4⁺ (**A**) or proliferating CD8⁺ (**B** and **C**) T cells coexpressing IFN γ and TNF α or CD107a ($n = 3$ patients per group). P value indicates the difference in changes between baseline and 3 to 6 months assessed with two-sided testing on the group (baseline, 3–6 months) by condition (no BCG, BCG) interaction term in a linear model. **D–F**, WT female C57BL/6 mice were challenged with subcutaneous MB49 tumors and treated with BCG intratumorally weekly for 3 weeks starting on day 5. For some experiments, (**D**) mice were sacrificed around day 25 when tumors were harvested for immune analysis mainly for H-2D^b-HY-Uty tetramer staining on CD8⁺ T cells (gated under FVD⁻CD45⁺CD3⁺CD8⁺ cells) using an unspecific peptide-loaded tetramer (H-2D^b/Ctrl) as negative control (top, examples of flow dot plots for gating strategy). AN of tetramer⁺ CD8⁺ T cells per 0.1 g of tumor tissue ($n = 7$ tumors per group) were calculated accordingly (bottom graph). Shown is representative of three independent experiments. Mean \pm SEM. Each dot represents one tumor; t test was applied accordingly after normality test was run. **E**, BCG groups (filled diamonds) compared with PBS control (open diamonds). After 45 days, mice with prior BCG treatment and regressed tumors (filled circles) were rechallenged with subcutaneous MB49 cells versus a cohort of naïve mice (open circles). Shown is representative of three independent experiments ($n =$ number of tumors). Two-way ANOVA for comparison of control versus treatment groups at either initial or secondary tumor challenge. Mean \pm SEM. T.R., tumor regressed. **F**, Prior BCG-treated/tumor-regressed mice were rechallenged with subcutaneous MB49 cells, as in **E**, with or without CD4 and/or CD8 T-cell depletion or isotype antibodies. Shown is representative of two independent experiments ($n =$ number of tumors). Repeated measures ANOVA with Dunnett multiple comparison test. Mean \pm SEM. *, $P < 0.05$; ***, $P < 0.001$; NS, not significant.

Ji et al.

growth during MB49 rechallenge (Fig. 1E) but were not protected against B16 melanoma tumor growth (Supplementary Fig. S2), consistent with BCG-mediated induction of tumor-specific antitumor immunity (15). To test whether BCG-induced antitumor protective immunity required $\alpha\beta$ T cells, we repeated experiments as in Fig. 1E but depleted CD4⁺ and/or CD8⁺ T cells during the MB49 rechallenge phase. Mice were still protected or partially protected against subsequent tumor challenge with depletion of CD4⁺ or CD8⁺ T cells alone but not with depletion of both (Fig. 1F), indicating that both CD4⁺ and CD8⁺ T cells contribute to BCG-mediated tumor-specific antitumor immunity in our model. Depletion of CD4⁺ and/or CD8⁺ T cells was confirmed in TDLNs at the end of study (Supplementary Fig. S3A–C). We also observed an increase in the percentage of $\gamma\delta$ T cells in TDLNs of mice depleted of all conventional $\alpha\beta$ T cells (Supplementary Fig. S3B, right graph).

BCG promotes tumor antigen-specific T cells

Prior studies propose that BCG treats bladder cancer through BCG-specific T cells that attack tumor cells expressing BCG antigens (10–13). In support of this, BCG vaccination improves subsequent antitumor responses to intravesical BCG in mice (14), a strategy currently being tested in humans (28, 34). Nevertheless, these data do not prove a BCG-specific immune mechanism explaining BCG treatment efficacy. To evaluate BCG-specific versus tumor-specific T-cell contributions toward BCG antitumor efficacy directly, we utilized a wide repertoire of antigens directly from live BCG, the male-HY antigen present on MB49 cells, and the nontumor OVA protein to generate BCG, tumor (HY), and control nontumor OVA antigen-specific T cells, respectively, for adoptive transfer experiments (Fig. 2A). ELISPOTs confirmed high frequency and specificity of antigen-specific T cells of each type (Fig. 2B). Following adoptive transfer of T cells into Rag1^{KO} mice, which lack all T cells, mice were challenged with subcutaneous MB49 and treated with intratumoral BCG or control (PBS). Compared with control-treated tumors, tumors treated with BCG had higher numbers of BCG-specific tumor-infiltrating CD4⁺ T cells (Fig. 2C). BCG treatment also reduced the frequency and amount of PD-1 expressed on tumor-infiltrating tumor HY-specific CD8⁺ T cells (Supplementary Fig. S4). These data suggest that BCG can boost both BCG and MB49 tumor antigen-specific T cells, by either promoting trafficking into the tumor, proliferation, or reinvigoration/reactivation inside the tumor microenvironment. BCG reduced tumor growth following adoptive transfer of tumor HY-specific T cells (Fig. 2D) but had no significant effect on tumor growth after adoptive transfer of BCG-specific (Fig. 2E) or non-tumor antigen-specific T cells (Fig. 2F). These findings indicate that BCG mediates antitumor activity, at least in part, by boosting tumor-specific T cells. However, the effect of BCG on tumor-specific T-cell control of tumor growth was modest (Fig. 2D) compared with the effects observed in WT mice (Fig. 1E, open vs. filled diamonds), and transfer of tumor-specific T cells alone did not reduce tumor growth compared with transfer of non-tumor-specific T cells (Fig. 2G), suggesting that additional immune cell subsets, lacking in Rag1^{KO} mice, contributed to BCG-mediated antitumor immunity and/or facilitated tumor-specific T-cell efficacy.

$\gamma\delta$ T cells contribute to BCG-mediated antitumor immunity in bladder cancer

We hypothesized that $\gamma\delta$ T cells are required for CD4⁺ and CD8⁺ $\alpha\beta$ T cell-mediated BCG antitumor effects because $\gamma\delta$ T cells rapidly expand and develop a memory-type response during BCG infection (35), as well as provide functional help for BCG-specific $\alpha\beta$ T


cells during BCG vaccination against tuberculosis (20). To test this hypothesis, we studied BCG treatment of MB49 tumor growth in TCR α ^{KO} mice [lack conventional $\alpha\beta$ T cells (36, 37)] and TCR δ ^{KO} mice (lack unconventional $\gamma\delta$ T cells). MB49 tumors grew faster in TCR α ^{KO} compared with TCR δ ^{KO} mice (Fig. 3A), regardless of BCG treatment, consistent with stronger antitumor protection of combined CD4⁺ and CD8⁺ $\alpha\beta$ T cells versus $\gamma\delta$ T cells. In the absence of $\gamma\delta$ T cells, BCG had no discernable treatment effect (Fig. 3A, triangles), consistent with a prior report (38). However, in the absence of $\alpha\beta$ T cells, BCG still significantly suppressed MB49 tumor growth (Fig. 3A, circles). BCG had no direct cytotoxicity against MB49 *in vitro* and depleting $\gamma\delta$ T cells with specific antibodies abolished the efficacy of BCG in TCR α ^{KO} mice, consistent with the contribution of $\gamma\delta$ T cells toward BCG's antitumor efficacy (Fig. 3B). To determine whether $\gamma\delta$ T cells facilitated antigen-specific immunity during BCG therapy, we adoptively transferred antigen-specific CD4⁺ and CD8⁺ T cells into TCR α ^{KO} mice, which restored BCG efficacy in reducing tumor growth using either tumor-specific (Fig. 3C) or BCG-specific T cells (Fig. 3D), but not with OVA-specific T cells (Fig. 3E). Adoptive transfer of tumor antigen-specific $\alpha\beta$ T cells significantly reduced tumor growth compared with transfer of non-tumor-specific T cells (Fig. 3F). Collectively, these data support a role for $\gamma\delta$ T cells in mediating BCG antitumor immunity both directly (i.e., without $\alpha\beta$ T cells) and indirectly through supporting effects for both tumor- and BCG-specific $\alpha\beta$ T cells. These data also show that BCG mediates antitumor effects, in part, through BCG-specific T cells.

Rapamycin boosts $\gamma\delta$ T-cell activity to improve BCG antitumor immunity

Given the role of $\gamma\delta$ T cells in BCG-mediated antitumor responses, we questioned whether improving $\gamma\delta$ T-cell function would boost BCG efficacy. The mTOR inhibitor, rapamycin, enhances $\gamma\delta$ T-cell function and antitumor immunity in mice (22) and patients with bladder cancer (25). To test whether rapamycin could augment BCG-mediated suppression of MB49 tumor growth, WT mice were challenged with subcutaneous MB49 and treated with \pm intratumoral BCG and \pm intraperitoneal rapamycin. BCG alone treated MB49, but their combination further decreased tumor growth (Fig. 4A). Similarly, BCG combined with oral encapsulated rapamycin (eRapa) was effective at slowing MB49 tumor growth (Supplementary Fig. S5). To determine whether the effects of the rapamycin/BCG combination therapy on MB49 tumor growth were mediated through $\gamma\delta$ T cells, we repeated experiments in TCR α ^{KO} mice, which lack CD4⁺ and CD8⁺ T cells but retain $\gamma\delta$ T cells. In TCR α ^{KO} mice challenged with MB49, rapamycin plus BCG significantly decreased tumor growth versus control (Fig. 4B), and this effect was abolished by $\gamma\delta$ T-cell depletion (Fig. 4C). In TCR α ^{KO} mice, rapamycin had no discernable effect on the number of tumor-infiltrating $\gamma\delta$ T cells (Fig. 4D and E) nor tumor-infiltrating $\gamma\delta$ T cells producing IFN γ , TNF α , or IL17 (Supplementary Fig. S6A). However, rapamycin significantly increased surface expression of $\gamma\delta$ TCR and activation markers CD44 and CD69 on tumor-infiltrating $\gamma\delta$ T cells in TCR α ^{KO} mice receiving BCG (Fig. 4F–H). Rapamycin also increased production of IFN γ within $\gamma\delta$ T cells, measured by fluorescence intensity (Supplementary Fig. S6A, middle-bottom graph). In these tumors, the majority (~80%) of tumor-infiltrating $\gamma\delta$ T cells are effector memory (EM) cells. In mice treated with BCG, rapamycin increased the percentage of EM $\gamma\delta$ T cells within tumors (Supplementary Fig. S6B). Conversely, combination of rapamycin and BCG decreased the percentage of both naïve and terminally differentiated effector memory (TDEM) $\gamma\delta$ T cells in the tumor compared with control (Supplementary Fig. S6B). These data

$\gamma\delta$ T Cells Support $\alpha\beta$ T Cells during BCG Treatment**Figure 2.**

BCG treatment increases tumor-infiltrating, adoptively transferred tumor-specific, or BCG-specific T cells in MB49-bearing Rag1^{KO} mice, but only tumor-specific T cells are protective. **A**, Generation and expansion of antigen (Ag)-specific T cells from donor mice by vaccination and *in vitro* Ag restimulation followed by IL2 prior to adoptive transfer. After MB49 tumor challenge, BCG treatment was given intratumorally (i.t.) weekly starting day 6 in recipients. After day 17, recipients were sacrificed, and tumors and TDLNs were processed for flow cytometry analysis. SPL, splenocytes. **B**, Ag specificity of enriched donor T cells was verified and quantified on the same day of adoptive transfer by mouse IFN γ ELISPOTS. Ctrl, naïve splenocytes alone as an ELISPOT control but not transferred to recipient mice. Shown is representative of three independent experiments. **C**, Flow cytometry for CD4⁺ and CD8⁺ tumor-infiltrating T cells in Rag1^{KO} recipients. Top, gating strategy based on TDLNs. Shown are results pooled from two independent experiments ($n = 4-9$ tumors per group). One-way ANOVA with Tukey multiple comparison test was applied according to normality testing. AN, absolute number. **D-G**, Subcutaneous tumor growth in Rag1^{KO} recipients (shown are pooled from three independent experiments, $n = 7-14$ tumors per group). For three groups, repeated measures ANOVA with Dunnett multiple comparison test. For two groups, two-way ANOVA. Mean \pm SEM. *, $P < 0.05$; **, $P < 0.01$; NS, not significant.




support a favorable antitumor effect of rapamycin during BCG treatment of MB49 bladder tumors, which requires EM $\gamma\delta$ T cells.

To test rapamycin's effects on human $\gamma\delta$ T cell-mediated antitumor activity, human peripheral blood $\gamma\delta$ T cells (the majority were $\gamma 9^+/\delta 2^+$) were expanded *in vitro* with IL2 and IPP as described previously (22) and cocultured with/without rapamycin and with/without BCG. After 14 days in culture, both rapamycin and BCG alone increased the number of expanded $\gamma 9^+/\delta 2^+$ T cells, and the combination of rapamycin plus BCG yielded the highest number of $\gamma 9^+/\delta 2^+$ T cells (Fig. 5A). Each agent alone and combination of rapamycin plus BCG had minimal effects on the percentage of IFN γ - or TNF α -producing $\gamma\delta$ T cells (Fig. 5B), nonetheless, significantly increased

the production of IFN γ and TNF α within $\gamma\delta$ T cells, as estimated by mean fluorescence intensity (Fig. 5C; Supplementary Fig. S7A). Consistent with other study for *in vitro*-expanded $\gamma\delta$ T cells from human PBMCs (39), the majority of $\gamma 9^+/\delta 2^+$ T were EM cells (75%–95%), regardless of treatment (Supplementary Fig. S7B). Rather than altering the profile/percentages of differentiated $\gamma 9^+/\delta 2^+$ T cells, rapamycin significantly increased the absolute number (AN) of EM $\gamma 9^+/\delta 2^+$ T cells compared with control with only IL2 and IPP in the culture. Combining rapamycin and BCG treatment yielded the lowest percentage of naïve $\gamma 9^+/\delta 2^+$ T cells (Supplementary Fig. S7B) and highest numbers of EM $\gamma 9^+/\delta 2^+$ T cells (Fig. 5D). To investigate rapamycin effects on $\gamma\delta$ T cell-mediated human bladder cancer killing *in vivo*,

Ji et al.

**Figure 3.**

BCG treatment efficacy and antigen-specific immunity boost require $\gamma\delta$ T cells. $\text{TCR}\alpha^{\text{KO}}$ and $\text{TCR}\delta^{\text{KO}}$ mice (pooled from two to three independent similar experiments, n = number of tumors per group; **A**), or $\text{TCR}\alpha^{\text{KO}}$ mice with depletion of $\gamma\delta$ T cells (representative of two similar experiments, n = number of tumors per group; **B**) were challenged with subcutaneous MB49 cells and treated with intratumoral BCG. Two-way ANOVA. Mean \pm SEM. **C-F**, Adoptive transfers as described in **Fig. 2A** but using $\text{TCR}\alpha^{\text{KO}}$ mice (pooled from three independent experiments, n = number of tumors per group). For three groups, repeated measures ANOVA with Dunnett multiple comparison test. For two groups, two-way ANOVA. Mean \pm SEM. *, $P < 0.05$; **, $P < 0.01$; NS, not significant.

cultured autologous $\gamma\delta$ T cells were comixed in a 1:2 ratio with PDX257S human bladder cancer cells before subcutaneous injection into NOD/SCID/IL2R γ -deficient mice that received no further treatment after tumor challenge as described (22). $\gamma\delta$ T cells cocultured with BCG did not inhibit PDX257S tumor growth, whereas rapamycin inhibited tumor growth moderately (Supplementary Fig. S7C); however, neither agent could improve survival (**Fig. 5E**). $\gamma\delta$ T cells cocultured with BCG plus rapamycin significantly decreased PDX257S tumor growth and improved survival in recipient mice compared with mice receiving control $\gamma\delta$ T cells or BCG-treated $\gamma\delta$ T cells (Supplementary Fig. S7C; **Fig. 5E**). Taken together, these data support a beneficial effect of rapamycin in combination with BCG to treat human bladder cancer through $\gamma\delta$ T cells.

Discussion


Although the efficacy of BCG in reducing the risk of bladder cancer relapse (1) and progression (40) has been known for decades, BCG antitumor mechanisms remain incompletely defined. Most T cell-based cancer immunotherapies mediate tumor killing through tumor-specific T cells, but the role of tumor-specific immunity in BCG's activity is not established. The first experiments to address BCG's antitumor mechanisms used intradermal hepatocarcinoma line 10 (L-10) in guinea pigs, animals in which BCG is highly immunogenic.

BCG can induce tumor immunity in weakly antigenic tumors if tumor cells are injected concurrently with live BCG (41) and shows evidence for eliciting protective antitumor immunity (42). BCG also mediates protective antitumor immunity in MBT-2 mouse bladder tumors (43). In both L-10 and MBT-2 tumor experiments, however, it is not clear whether BCG-mediated protection against cancer growth is tumor specific or nonspecific, such as through priming or activation of T cells reactive to nontumor peptides. Other studies have been unable to demonstrate tumor-specific immunity during BCG treatment of bladder cancer (7, 44).

Using MHC class I tetramers, we demonstrated that BCG increased tumor antigen-specific T cells in both tumor and TDLNs during bladder cancer treatment. Successful treatment of bladder cancer by BCG induced protective tumor-specific immune memory against subsequent bladder tumor rechallenge. BCG was effective in treating bladder tumors in mice bearing tumor-specific or BCG-specific T cells but not in mice bearing non-tumor-specific T cells. These data support antigen-specific mechanisms underlying BCG's antitumor activity, but with only a modest contribution toward BCG's treatment efficacy because BCG-specific T cells can reduce tumor growth with the presence of live BCG. Although a subset of patients with bladder cancer derive long-term benefit from 6 weekly BCG instillations (i.e., BCG induction; ref. 1), maintenance BCG with repeated instillations over 3 years is needed for long-term control (4). BCG efficacy is contact

Figure 4.

Rapamycin improves $\gamma\delta$ T-cell activity to boost BCG-mediated antitumor immunity in mice. **A**, WT mice challenged subcutaneously with MB49 and treated with rapamycin (Rapa), BCG, or both starting on day 5. Shown is representative from two similar experiments (n = number of tumors per group). Repeated measures ANOVA with Dunnett multiple comparison test. Mean \pm SEM. **B** and **C**, $\text{TCR}\alpha^{\text{KO}}$ mice challenged subcutaneously with MB49 and treated with rapamycin, BCG, or with $\gamma\delta$ T-cell depletion (representative of two to three independent experiments, n = number of tumors per group). **B**, Repeated measures ANOVA with Dunnett multiple comparison test. Mean \pm SEM. **C**, Two-way ANOVA. Mean \pm SEM. **D–H**, $\text{TCR}\alpha^{\text{KO}}$ mice treated as in **B** were sacrificed on day 18 for flow cytometry analysis of available tumors (n = 6–10 tumors per group). Gating strategies of tumor-infiltrating $\gamma\delta$ T cells are shown in **D** as $\text{FVD}^{-}\text{CD45}^{+}\text{CD3}^{+}\gamma\delta\text{TCR}^{+}$ (top) and in **G** and **H** for cell surface expression of CD44 and CD69 with FMO control (top). **E**, Absolute number (AN) of $\gamma\delta$ T cells per 0.1 g of tumor tissue was calculated on the basis of the percentage of $\gamma\delta$ T cells out of total live tumor single-cell suspensions. **F**, Mean fluorescence intensity (MFI) is shown to indicate $\gamma\delta$ TCR expression level. **G** and **H**, Frequency of activation marker (CD44 and CD69) expression on $\gamma\delta$ T cells (bottom graphs). Shown are representative of two independent experiments. One-way ANOVA with Tukey or Dunn multiple comparison test was applied according to normality testing. Mean \pm SEM. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; NS, not significant.



dependent, with little activity on distant urothelial sites (7). These data are not consistent with BCG generating effective long-term systemic tumor-specific immunity. The improved efficacy provided by maintenance BCG could be explained by boosting poorly durable tumor-specific immunity, or by continually activating nonspecific immune mechanisms.

A non-tumor-specific T-cell mechanism proposed for BCG-mediated efficacy is the activation of BCG-specific T cells that eliminate tumors expressing BCG-derived antigens, which could occur by BCG internalization into bladder tumors (45–47). The concept of BCG-specific immunity boosting antitumor responses is supported by animal studies showing that intradermal BCG

vaccination in mice boosts the antitumor activity of intravesical BCG and accelerates infiltration of T cells into the bladder in bladder cancer (14). This concept is currently being tested in humans (34). We found direct evidence that BCG-specific T cells can contribute to BCG-mediated antitumor activity in mice by using the full repertoire of antigen-specific T cells against live BCG, providing more supportive data compared with studies using antigen-specific T cells against a single antigen (15). It is not clear whether BCG uptake occurs equally in normal and malignant urothelium. Understanding mechanisms for BCG uptake by urothelial cells is needed and could identify approaches to enhance selective BCG uptake by transformed cells.

Ji et al.




Figure 5.

Rapamycin improves $\gamma\delta$ T-cell activity to boost BCG-mediated antitumor immunity against human bladder cancer cells. Autologous human PBMCs from the PDX (PDX257S) donor were expanded *in vitro* for $\gamma\delta$ T cells for 14 days, and then cocultured with rapamycin, BCG, or both *in vitro*, followed by quantification and flow cytometry analysis. **A**, Absolute number (AN) of expanded total live CD3⁺ $\gamma\delta$ T cells (mostly $\gamma 9^{+}/\delta 2^{+}$ T cells) from 0.25×10^6 PBMCs and frequency. Rapa, rapamycin. Frequency of IFN γ and TNF α expression (**B**) or production (fluorescent intensity) of IFN γ and TNF α (**C**) in $\gamma 9^{+}/\delta 2^{+}$ T cells after 5 hours of stimulation with cell activation cocktail (see "Materials and Methods"). **D**, AN of differentiated $\gamma 9^{+}/\delta 2^{+}$ T expanded from 0.25×10^6 PBMCs in day 14 of culture ($n = 4$ replicated samples per treatment group from one representative experiment). Gating strategies for differentiated $\gamma\delta$ T cells are as follows: naïve, CD45RA⁺CD27⁺; central memory (CM), CD45RA⁻CD27⁺; EM, CD45RA⁻CD27⁻; and TDEM, CD45RA⁺CD27⁻. **A–C**, Shown are representative of two similar experiments, in quadruplicates for each treatment condition. **A** and **B**, One-way

We validated prior findings that $\gamma\delta$ T cells are indispensable for eliciting BCG treatment efficacy against bladder cancer in mice (38) and our previous study showing the utility of targeting $\gamma\delta$ T cells in bladder with other immunotherapy approaches (48). Our data support both direct and indirect antitumor effects of $\gamma\delta$ T cells, with the latter through antigen-specific $\alpha\beta$ T cells. The mechanisms by which $\gamma\delta$ T cells support conventional T cells during BCG therapy is not fully clear and requires further investigation. Upon activation, $\gamma\delta$ T cells can promote the maturation and function of dendritic cells (DC) to enhance $\alpha\beta$ T-cell responses (49), or can be induced to take up and process microbial and tumor soluble proteins, thereby serving as professional antigen-presenting cells (50, 51). Activated $\gamma\delta$ T cells are also capable of cross-priming, in which soluble proteins are taken up and processed for presentation on MHC class I molecules for CD8⁺ T-cell activation (52). One report found that $\gamma\delta$ T cells were more effective as antigen-presenting cells than DCs in inducing CD8⁺ T-cell proliferation, cytokine production, and target cell killing (52), but we are unaware of whether they can mediate T-cell priming. We observed an increase amount of MHC class I expression per $\gamma\delta$ T cell during BCG therapy at later stages of tumor growth, suggesting that BCG could enhance their ability to present antigens as tumors progressed, but further work is required to understand how $\gamma\delta$ T cells cooperate with conventional T cells to mediate antigen-specific immunity, especially in the context of combining rapamycin and BCG treatment.

The direct antitumor activity of $\gamma\delta$ T cells correlates with their differentiation status, that is, ability to migrate, proliferate, and produce effector cytokines. Central memory (CM) cells are highly proliferative with low IFN γ production, whereas EM cells are less proliferative but can produce more IFN γ (53–56). Consistent with studies of profiling either *in vitro* PBMC-expanded or tumor-infiltrating $\gamma\delta$ T cells from patients with cancer (39, 57), we found that the majority of $\gamma\delta$ T cells in mouse MB49 tumors or *in vitro*-expanded human $\gamma 9^{+}/\delta 2^{+}$ T cells were largely EM cells. As expected, resident memory $\gamma\delta$ T cells were infrequent among mouse tumor infiltrates ($\leq 5\%$) and rare among *in vitro*-expanded human PBMCs ($\leq 0.01\%$). In mouse tumors, rapamycin increased the percentage of EM cells during BCG therapy and decreased TDEM and naïve $\gamma\delta$ T cells with or without the treatment of BCG, respectively, which supports favorable effects of rapamycin on $\gamma\delta$ T-cell antitumor function. In contrast, for human *in vitro*-expanded $\gamma 9^{+}/\delta 2^{+}$ T cells, rapamycin did not alter the overall differentiation status/profile of $\gamma\delta$ T cells, except for inducing the lowest percentage of naïve $\gamma\delta$ T cells in the presence of BCG. However, rapamycin significantly increased the AN of human EM $\gamma 9^{+}/\delta 2^{+}$ T cells with or without BCG in the culture compared with control. Although these data demonstrate differences in rapamycin's effect on murine versus human $\gamma\delta$ T cells, in both species, rapamycin predominately acted on the EM population. Further evidence for an effect on $\gamma\delta$ T cells effector memory function was shown by the combination of rapamycin plus BCG, which increased IFN γ production in $\gamma\delta$ T cells in both mouse and human models.

ANOVA with Tukey multiple comparison test. Mean \pm SEM. **C**, One-way ANOVA with Bonferroni multiple comparison test was applied using mean, SEM, and N of each group. **D**, One-way ANOVA with Tukey multiple comparison after normality test. Mean \pm SEM. **E**, NSG mice were subcutaneously challenged with human PDX257S bladder cancer cells mixed with autologous PBMC-derived $\gamma\delta$ T cells. Tumor volume $> 1,500 \text{ mm}^3$ was used as survival cutoff. Kaplan–Meier plot with log-rank test. Shown is the representative of two independent experiments ($n = 6$ tumors per group). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; NS, not significant.

Although mouse tumor models enable exploration of BCG antitumor mechanisms, interpretations here are limited by differences between mouse and human $\gamma\delta$ T cells, which respond differently to mycobacterial antigens. Murine $\gamma\delta$ T cells poorly recognize phosphoantigens (58, 59), whereas human BCG vaccination induces the expansion of V γ 2V δ 2 and γ 9 $^+$ δ 2 $^+$ T cells reactive with isopentenyl pyrophosphates (20, 60, 61). Further work is needed to understand the relevance of human $\gamma\delta$ T cells toward response to BCG in patients.

Combining rapamycin with BCG could be useful in treating bladder cancer because mTOR inhibition improves antigen-specific immunity (62–64) and enhances BCG peptide presentation (65, 66). In combination with anti-CLTA-4, an immune checkpoint inhibitor, rapamycin increases immune responses against EL4 lymphoma (29). Our studies further show that rapamycin enhances MHC-independent $\gamma\delta$ T cell-mediated BCG antitumor immunity to treat both mouse and human bladder cancer. Our previous phase I clinical trial addresses the safety and tolerability of mTOR inhibition in combination with intravesical BCG and shows that low-dose rapamycin does not exacerbate BCG-related symptoms, while boosting peripheral BCG-specific and urinary $\gamma\delta$ T cells (25). Further work and a phase II clinical trial are underway to reveal the underlying mechanism and clinical efficacy of combination rapamycin and BCG treatment in terms of bladder tumor progression and survival of patients.

Conclusion

BCG treatment of bladder cancer induces a tumor-specific memory response by boosting the activity of tumor-specific T cells. BCG antigen-specific T cells also contribute to BCG's antitumor activity, presumably by targeting BCG-derived peptides presented by MHC molecules on bladder tumors. BCG-mediated activation of conventional $\alpha\beta$ T cells, however, requires nonconventional $\gamma\delta$ T cells, which have innate immune features, supporting a role for both adaptive and innate immunity in BCG's antitumor effects. In an experimental model of human bladder cancer, rapamycin improved human $\gamma\delta$ T cell-mediated bladder cancer control. Collectively, our results identify immune mechanisms for bladder cancer treatment properties of BCG and support evaluation of rapamycin plus BCG for treating patients with non-muscle-invasive bladder cancer.

References

- Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. *N Engl J Med* 1991;325:1205–9.
- Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. *Surgery* 1970;68:158–63.
- Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. *J Urol* 1976;116:180–2.
- Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. *J Urol* 2000;163:1124–9.
- Witjes JA. Management of BCG failures in superficial bladder cancer: a review. *Eur Urol* 2006;49:790–7.
- Ratliff TL, Gillen D, WJ C. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. *J Urol* 1987;137:155–8.
- Ratliff TL, Ritchey JK, Yuan JJJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. *J Urol* 1993;150:1018–23.
- Mayordomo JL, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Faló LD, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. *Nat Med* 1995;1:1297–302.
- Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C, et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. *Blood* 2005;105:2465–72.
- Luo Y, Szilvasi A, Chen X, DeWolf WC, O'Donnell MA. A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. *Clin Diagn Lab Immunol* 1996;3:761–8.
- Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. *J Clin Invest* 1990;85:62–67.
- Ratliff TL, Palmer JO, McGarr JA, Brown EJ. Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. *Cancer Res* 1987;47:1762–6.
- Lattime EC, Gomella LG, McCue PA. Murine bladder carcinoma cells present antigen to BCG-specific CD4 $^+$ T-cells. *Cancer Res* 1992;52:4286–90.
- Biot C, Rentsch CA, Gsponer JR, Birkhauser FD, Jusforgues-Saklani H, Lemaitre F, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. *Sci Transl Med* 2012;4:137ra72.

Authors' Disclosures

J.J. Meeks reports other support from Merck, AstraZeneca, Ferring Pharmaceuticals, Janssen, Bristol Myers Squibb, Foundation Medicine, UroGen, and Olympus outside the submitted work. D.J. McConkey reports grants from Department of Defense during the conduct of the study, as well as grants from AstraZeneca, personal fees from Janssen and H3 Biomedicine, and grants and personal fees from Rainier Pharmaceuticals outside the submitted work. R.S. Svatek reports nonfinancial support from Japanese BCG Laboratories and Rapamycin Holdings during the conduct of the study, as well as other support from Ferring Pharmaceuticals outside the submitted work. No disclosures were reported by the other authors.

Authors' Contributions

N. Ji: Conceptualization, resources, data curation, software, formal analysis, supervision, funding acquisition, validation, investigation, visualization, methodology, writing—original draft, project administration, writing—review and editing. N. Mukherjee: Resources, funding acquisition, writing—original draft, writing—review and editing. Z.-J. Shu: Resources, data curation, methodology. R.M. Reyes: Resources, funding acquisition, writing—review and editing. J.J. Meeks: Writing—review and editing. D.J. McConkey: Writing—review and editing. J.A. Gelfond: Formal analysis, writing—review and editing. T.J. Curriel: Conceptualization, resources, software, funding acquisition, writing—review and editing. R.S. Svatek: Conceptualization, resources, data curation, software, formal analysis, supervision, funding acquisition, validation, investigation, visualization, methodology, writing—original draft, project administration, writing—review and editing.

Acknowledgments

The work was supported by following funding: (i) the Glenda and Gary Woods Distinguished Chair in GU Oncology; (ii) 8KL2 TR000118, K23; (iii) the Mays Family Cancer Center at UT Health San Antonio (P30 CA054174); (iv) the Roger L. and Laura D. Zeller Charitable Foundation Chair in Urologic Cancer; (v) the Max & Minnie Tomerlin Voelcker Fund; (vi) CDMRP CA170270/P1P2; (vii) the Bladder Cancer Advocacy Network (BCAN) 2016 Young Investigator Award; (viii) a Research Training Award (RP170345) from the Cancer Prevention & Research Institute of Texas; (ix) the MSTP Program (NIH T32GM113896); (x) NIH/NCATS TL1 TR002647; and (xi) NIA T32 AG 021890.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 15, 2021; revised July 26, 2021; accepted September 30, 2021; published first October 4, 2021.

Ji et al.

15. Antonelli AC, Binyamin A, Hohl TM, Glickman MS, Redelman-Sidi G. Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-gamma signaling. *Proc Natl Acad Sci U S A* 2020;117:18627–37.
16. Schild H, Mavaddat N, Litzenberger C, Ehrlich EW, Davis MM, Bluestone JA, et al. The nature of major histocompatibility complex recognition by gamma delta T cells. *Cell* 1994;76:29–37.
17. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. *Nature* 1995;375:155–8.
18. Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, Lim RT, et al. CD1d-lipid antigen recognition by the gammadelta TCR. *Nat Immunol* 2013;14:1137–45.
19. Constant P, Poquet Y, Peyrat MA, Davodeau F, Bonneville M, Fournié JJ. The antituberculous *Mycobacterium bovis* BCG vaccine is an attenuated mycobacterial producer of phosphorylated nonpeptidic antigens for human gamma delta T cells. *Infect Immun* 1995;63:4628–33.
20. Hoft DF, Brown RM, ST R. Bacille Calmette-Guerin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. *J Immunol* 1998;161:1045–54.
21. Cao G, Wang Q, Li G, Meng Z, Liu H, Tong J, et al. mTOR inhibition potentiates cytotoxicity of Vgamma4 gammadelta T cells via up-regulating NKG2D and TNF-alpha. *J Leukoc Biol* 2016;100:1181–9.
22. Dao V, Liu Y, Pandeswara S, Svatek RS, Gelfond JA, Liu A, et al. Immunostimulatory effects of rapamycin are mediated by stimulation of antitumor gammadelta T cells. *Cancer Res* 2016;76:5970–82.
23. Li H, Pauza CD. Rapamycin increases the yield and effector function of human gammadelta T cells stimulated in vitro. *Cancer Immunol Immunother* 2011;60:361–70.
24. Svatek RS, Ji N, de Leon E, Mukherjee NZ, Kabra A, Hurez V, et al. Rapamycin prevents surgery-induced immune dysfunction in patients with bladder cancer. *Cancer Immunol Res* 2018;4:66–75.
25. Ji N, Mukherjee N, Reyes RM, Gelfond J, Javors M, Meeks JJ, et al. Rapamycin enhances BCG-specific gammadelta T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. *J Immunother Cancer* 2021;9:e001941.
26. Chen ZW. Immune regulation of gammadelta T cell responses in mycobacterial infections. *Clin Immunol* 2005;116:202–7.
27. Holderness J, Hedges JF, Ramstead A, Jutila MA. Comparative biology of gammadelta T cell function in humans, mice, and domestic animals. *Annu Rev Anim Biosci* 2013;1:99–124.
28. Ji N, Mukherjee N, Morales EE, Tomasini ME, Hurez V, Curiel TJ, et al. Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial. *Oncoimmunology* 2019;8:1614857.
29. Pedicord VA, Cross JR, Montalvo-Ortiz W, Miller ML, Allison JP. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. *J Immunol* 2015;194:2089–98.
30. Liu Y, Pandeswara S, Dao V, Padrón Á, Drerup JM, Lao S, et al. Biphasic rapamycin effects in lymphoma and carcinoma treatment. *Cancer Res* 2017;77:520–31.
31. Ji N, Somanaboeina A, Dixit A, Kawamura K, Hayward NJ, Self C, et al. Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis. *J Immunol* 2013;191:5074–84.
32. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. *J Exp Med* 2009;206:1457–64.
33. Zaharoff DA, Hoffman BS, Hooper HB, Benjamin CJ, Khurana KK, Hance KW, et al. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. *Cancer Res* 2009;69:6192–9.
34. Meeks JJ, Lerner SP, Svatek RS. Bacillus calmette-guerin manufacturing and SWOG S1602 intergroup clinical trial. *J Urol* 2017;197:538–40.
35. Shen Y, Zhou D, Qiu L, Lai X, Simon M, Shen L, et al. Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. *Science* 2002;295:2255–8.
36. Lindroth K, Troye-Blomberg M, Singh M, Dieli F, Ivanyi J, Fernández C. The humoral response in TCR alpha-/- mice. Can gammadelta-T cells support the humoral immune response? *Scand J Immunol* 2002;55:256–63.
37. Viney JL, Dianda L, Roberts SJ, Wen L, Mallick CA, Hayday AC, et al. Lymphocyte proliferation in mice congenitally deficient in T-cell receptor alpha beta + cells. *Proc Natl Acad Sci U S A* 1994;91:11948–52.
38. Takeuchi A, Dejima T, Yamada H, Shibata K, Nakamura R, Eto M, et al. IL-17 production by gammadelta T cells is important for the antitumor effect of *Mycobacterium bovis* bacillus Calmette-Guerin treatment against bladder cancer. *Eur J Immunol* 2011;41:246–51.
39. Ou L, Wang H, Liu Q, Zhang J, Lu H, Luo L, et al. Dichotomous and stable gamma delta T-cell number and function in healthy individuals. *J Immunother Cancer* 2021;9:e002274.
40. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. *J Urol* 2002;168:1964–70.
41. Zbar B, Bernstein I, Tanaka T, Rapp HJ. Tumor immunity produced by the intradermal inoculation of living tumor cells and living *Mycobacterium bovis* (strain BCG). *Science* 1970;170:1217–8.
42. Zbar B, Rapp HJ. Immunotherapy of guinea pig cancer with BCG. *Cancer* 1974;34:1532–40.
43. Reichert DF, Lamm DL. Long term protection in bladder cancer following intravesical immunotherapy. *J Urol* 1984;132:570–3.
44. Cornel EB, Van Moorselaar RJA, Van Stratum P, Debruyne FMJ, Schalken JA. Antitumor effects of bacillus Calmette-Guerin in a syngeneic rat bladder tumor model system, RBT323. *J Urol* 1993;149:179–82.
45. Ratliff TL, McCarthy R, Telle WB, Brown EJ. Purification of a mycobacterial adhesin for fibronectin. *Infect Immun* 1993;61:1889–94.
46. Schorey JS, Holsti MA, Ratliff TL, Allen PM, Brown EJ. Characterization of the fibronectin-attachment protein of *Mycobacterium avium* reveals a fibronectin-binding motif conserved among mycobacteria. *Mol Microbiol* 1996;21:321–9.
47. Schorey JS, Li Q, McCourt DW, Bong-Mastek M, Clark-Curtiss JE, Ratliff TL, et al. A *Mycobacterium leprae* gene encoding a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells. *Infect Immun* 1995;63:2652–7.
48. Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, et al. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from alphaPD-L1 and include tissue-selective gamma delta T cell activation. *J Immunother Cancer* 9;2021:e002051.
49. Ismaili J, Olislagers V, Poupot R, Fournié J-J, Goldman M. Human gamma delta T cells induce dendritic cell maturation. *Clin Immunol* 2002;103:296–302.
50. Muto M, Baghdadi M, Maekawa R, Wada H, Seino KI. Myeloid molecular characteristics of human gammadelta T cells support their acquisition of tumor antigen-presenting capacity. *Cancer Immunol Immunother* 2015;64:941–9.
51. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. *Science* 2005;309:264–8.
52. Brandes M, Willimann K, Bioley G, Levy N, Eberl M, Luo M, et al. Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. *Proc Natl Acad Sci U S A* 2009;106:2307–12.
53. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. *J Exp Med* 2003;198:391–7.
54. Caccamo N, Meraviglia S, Ferlazzo V, Angelini D, Borsellino G, Poccia F, et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. *Eur J Immunol* 2005;35:1764–72.
55. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human [gamma]delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. *Cancer Res* 2007;67:7450–7.
56. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. *Clin Exp Immunol* 2010;161:290–7.
57. Cordova A, Toia F, La Mendola C, Orlando V, Meraviglia S, Rinaldi G, et al. Characterization of human gammadelta T lymphocytes infiltrating primary malignant melanomas. *PLoS One* 2012;7:e49878.
58. Griffin JP, Harshan KV, Born WK, Orme IM. Kinetics of accumulation of gamma delta receptor-bearing T lymphocytes in mice infected with live mycobacteria. *Infect Immun* 1991;59:4263–5.
59. Dieli F, Ivanyi J, Marsh P, Williams A, Naylor I, Sireci G, et al. Characterization of lung gamma delta T cells following intranasal infection with *Mycobacterium bovis* bacillus Calmette-Guerin. *J Immunol* 2003;170:463–9.

$\gamma\delta$ T Cells Support $\alpha\beta$ T Cells during BCG Treatment

60. Morita CT, Mariuzza RA, Brenner MB. Antigen recognition by human gamma delta T cells; pattern recognition by the adaptive immune system. *Springer Semin Immunopathol* 2000;22:191–217.
61. Zufferey C, Germano S, Dutta B, Ritz N, Curtis N. The contribution of non-conventional T cells and NK cells in the mycobacterial-specific IFN γ response in Bacille Calmette-Guerin (BCG)-immunized infants. *PLoS One* 2013; 8:e77334.
62. Keating R, Hertz T, Wehenkel M, Harris TL, Edwards BA, McClaren JL, et al. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. *Nat Immunol* 2013;14:1266–76.
63. Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, et al. Rapalogs efficacy relies on the modulation of antitumor T-cell immunity. *Cancer Res* 2016;76:4100–12.
64. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. mTOR inhibition improves immune function in the elderly. *Sci Transl Med* 2014;6:268ra179.
65. Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL, Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. *Nat Med* 2009;15:267–76.
66. Jagannath C, Bakhru P. Rapamycin-induced enhancement of vaccine efficacy in mice. *Methods Mol Biol* 2012;821:295–303.

Cancer Immunology Research

$\gamma\delta$ T Cells Support Antigen-Specific $\alpha\beta$ T cell –Mediated Antitumor Responses during BCG Treatment for Bladder Cancer

Niannian Ji, Neelam Mukherjee, Zhen-Ju Shu, et al.

Cancer Immunol Res 2021;9:1491-1503. Published OnlineFirst October 4, 2021.

Updated version Access the most recent version of this article at:
doi:[10.1158/2326-6066.CIR-21-0285](https://doi.org/10.1158/2326-6066.CIR-21-0285)

Supplementary Material Access the most recent supplemental material at:
<http://cancerimmunolres.aacrjournals.org/content/suppl/2021/10/02/2326-6066.CIR-21-0285.DC1>

Cited articles This article cites 65 articles, 29 of which you can access for free at:
<http://cancerimmunolres.aacrjournals.org/content/9/12/1491.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerimmunolres.aacrjournals.org/content/9/12/1491>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.